Cookies on the BTG website

We use cookies to ensure that we give you the best experience on our website.

If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the BTG website.

Find out more
Continue

About Us

Utilities
Print
Email
Email to a friend
Email to a friend

* Required

History

We have a rich heritage spanning many decades, from our successful commercialisation of intellectual property to our transformation into a specialist healthcare company.

Along the way we have partnered with some of the world’s leading healthcare companies and played a part in the development of a number of significant medical innovations. Most recently, we have created a growing specialist healthcare company that is focused on meeting the needs of specialist physicians and their patients.

DateMilestone
2013Acquisition of EKOS Corporation; Acquisition of TheraSphere®; Completed the sale of our brachytherapy business to Eckert & Ziegler BEBIG s.a.; Varithena® (polidocanol injectable foam) 1% approved in the US
2012Voraxaze® (glucarpidase) approved and launched in the US; Positive results reported from US pivotal Phase III trials of Varithena® (polidocanol injectable foam); US and EU approve expanded Zytiga® (abiraterone acetate) indication for treatment of metastatic castration-resistant prostate cancer
2011Acquisition of Biocompatibles International plc; Zytiga® approved in the US and EU; DigiFab® (digoxin immune fab (ovine)) receives first European regulatory approval
2010
BTG commences selling its own products in the US; Varithena® (polidocanol injectable foam) commences Phase III trials in the US
2009AstraZeneca initiates global Phase IIb study of AZD9773 (CytoFab)
2008Acquisition of Protherics PLC
2006Divestment of the majority of the physical sciences IP portfolio
2005Strategic business review leads to focus on life sciences
2003Nobel Prize for Medicine awarded to inventor of MRI, a technology first licensed by BTG in the 1980s
2002US launch of DigiFab®, a treatment for the toxic effects of over dosage with the heart drug digoxin
2001US launch of CroFab® (crotalidae polyvalent immune fab (ovine)), the first new rattlesnake antivenom on the US market in 50 years; US approval of Campath® (alemtuzumab) and EU approval of MabCampath® (alemtuzumab) for chronic lymphocytic leukaemia
1997BeneFIX® (coagulation factor IX (recombinant)) treatment for haemophilia B launched in the US
1996Following settlement with Johnson & Johnson for the Two-Part Hip Cup patents, BTG licensed them to all major orthopaedic companies.
1995BTG plc is listed on the London Stock Exchange (LSE:BGC (now LSE:BTG))
1992BTG is privatised
1981BTG is formed from the merger of the National Research & Development Council and the National Enterprise Board
1970sDevelopment and launch of: cholesterol assay tests; MRI; Oxford three-part knee
1960sPatenting/development of: continuously variable transmission; cephalosporin antibiotics; pyrethrin insecticides
1950sPatenting of interferon
1948National Research Development Corporation founded by UK government to commercialise publicly funded research
Maximising the potential of our assets
maximising potential

Our partnered programmes includes several products which we believe may have significant commercial potential.

BTG today
BTG today

We've undergone significant change in recent years, streamlining the business to focus on what we do best.